```html

Zollinger‑Ellison‑Like Gastrin Hypersecretion

Overview

Zollinger‑Ellison‑like gastrin hypersecretion refers to a condition in which the stomach produces an abnormally high amount of the hormone gastrin without the presence of a classic Zollinger‑Ellison syndrome (ZES). The excess gastrin stimulates the parietal cells of the stomach to secrete large volumes of gastric acid, leading to ulcer formation, diarrhea, and a range of other gastrointestinal symptoms. Unlike ZES—where a gastrin‑producing neuroendocrine tumor (gastrinoma) is identified—Zollinger‑Ellison‑like hypersecretion may be caused by functional hyperplasia of gastrin‑producing cells, chronic use of proton‑pump inhibitors (PPIs), or other non‑neoplastic mechanisms.

Who it affects: The condition can appear at any age but is most commonly diagnosed in adults between 30 and 60 years old. Women and men are affected roughly equally, although some studies suggest a slight female predilection when the hypersecretion is related to chronic PPI use (NIH, 2020).

Prevalence: True ZES is rare (≈1–3 cases per million per year). Zollinger‑Ellison‑like gastrin hypersecretion without an identifiable tumor is not well‑captured in epidemiologic databases, but retrospective series from tertiary centers estimate that up to 10 % of patients evaluated for refractory peptic ulcer disease have elevated gastrin levels without a detectable gastrinoma (Cleveland Clinic, 2022).

Symptoms

Because excess gastric acid affects the entire upper gastrointestinal (GI) tract, the symptom profile can be broad. All patients do not experience every symptom, and severity often correlates with the level of acid output.

• Abdominal pain or burning sensation – usually epigastric, may worsen after meals.
• Recurrent or refractory peptic ulcers – ulcers that fail to heal with standard therapy; they can appear in the duodenum, jejunum, or even the distal small bowel.
• Diarrhea – hyperacidic chyme inactivates pancreatic enzymes and damages the mucosa, leading to watery stools; may be chronic.
• Steatorrhea (fatty stools) – malabsorption of fat due to pancreatic enzyme inactivation; stools may be pale, foul‑smelling, and float.
• Nausea and vomiting – especially after large meals.
• Weight loss – from malabsorption, chronic diarrhea, or avoidance of food due to pain.
• Heartburn and gastroesophageal reflux disease (GERD) – acid overload can overwhelm the lower esophageal sphincter.
• Gastric bleeding – visible as melena (black, tarry stools) or hematemesis (vomiting blood).
• Iron‑deficiency anemia – chronic blood loss from ulcerations or impaired iron absorption in an acidic environment.
• Osteoporosis/osteopenia – long‑term acid excess can interfere with calcium absorption.

Causes and Risk Factors

Unlike classic ZES, which is almost always caused by a gastrinoma, Zollinger‑Ellison‑like gastrin hypersecretion may arise from several non‑neoplastic mechanisms.

Non‑neoplastic causes

• Chronic proton‑pump inhibitor (PPI) therapy – prolonged acid suppression leads to a feedback increase in gastrin secretion (hypergastrinemia). In rare cases, this compensatory rise becomes excessive and symptomatic (NIH, 2020).
• Chronic Helicobacter pylori infection – H. pylori colonization of the antrum can stimulate G‑cells, raising gastrin levels.
• Atrophic gastritis affecting the gastric body – loss of acid‑producing parietal cells triggers a compensatory rise in gastrin (type II hypergastrinemia).
• Renal failure – impaired clearance of gastrin can cause modest elevations, rarely reaching symptomatic levels.

Neoplastic causes (must be ruled out)

• Gastrinoma (Zollinger‑Ellison syndrome) – a neuroendocrine tumor most often located in the pancreas or duodenum; accounts for < 5 % of hypergastrinemia cases.
• Carcinoid tumors – less common, but can secrete gastrin.

Risk factors

• Long‑term (> 2 years) use of high‑dose PPIs or H2‑receptor antagonists.
• History of chronic H. pylori infection not eradicated.
• Familial endocrine tumor syndromes (MEN 1) – even if a gastrinoma has not yet been identified.
• Chronic kidney disease (stage 3–5).
• Age > 40 years (because the cumulative exposure to PPIs and H. pylori increases).

Diagnosis

Accurate diagnosis hinges on confirming elevated gastrin levels, ruling out a gastrinoma, and demonstrating the physiologic consequence—excess gastric acid.

Step‑by‑step diagnostic algorithm

1. Clinical suspicion – refractory ulcer disease, unexplained diarrhea, or recurrent ulcers despite standard therapy.
2. Fasting serum gastrin measurement – drawn after an overnight fast (≥ 8 hours). Levels > 100 pg/mL are abnormal; values > 1,000 pg/mL strongly suggest ZES, but lower elevations can be seen with non‑neoplastic hypersecretion (Mayo Clinic).
3. Secretin stimulation test – administration of secretin (2 U/kg IV) should paradoxically raise gastrin > 120 pg/mL in ZES; a lack of response helps exclude a gastrinoma.
4. Upper endoscopy (EGD) – visualizes ulcer location, assesses for bleeding, and enables biopsy to exclude malignancy or H. pylori.
5. Imaging for gastrinoma – if gastrin > 1,000 pg/mL or secretin test positive, cross‑sectional imaging (triphasic CT or MRI) and somatostatin receptor scintigraphy (Octreoscan) are performed.
6. H. pylori testing – urea breath test, stool antigen, or biopsy; eradication is required if positive.
7. Renal function assessment – serum creatinine and eGFR to gauge gastrin clearance.

It is essential to discontinue PPIs for at least 7 days (or H2 blockers for 48 hours) before measuring fasting gastrin, as these drugs can artificially raise levels (CDC, 2021).

Treatment Options

Treatment is aimed at three goals: suppress gastric acid, address the underlying cause of hypergastrinemia, and heal existing ulcers.

Medications

• Proton‑pump inhibitors (PPIs) – high‑dose regimens (e.g., omeprazole 60 mg daily or equivalent) are first‑line; they effectively reduce acid output by > 90 %.
• Potassium‑competitive acid blockers (PCABs) – newer agents such as vonoprazan provide rapid and sustained acid suppression and may be useful in PPI‑refractory cases (JAMA, 2022).
• H2‑receptor antagonists – cimetidine, ranitidine (where available) can be added for breakthrough symptoms but are less potent than PPIs.
• Somatostatin analogues (e.g., octreotide) – indicated when a gastrinoma is discovered or when hypergastrinemia persists despite maximal acid suppression.
• Antibiotic eradication therapy – standard triple or quadruple regimens for H. pylori (e.g., clarithromycin‑based triple therapy).
• Calcium and vitamin D supplementation – for patients with long‑term acid suppression to prevent osteoporosis.

Procedural Interventions

• Endoscopic ulcer therapy – hemostasis (heater probe, clips) for active bleeding.
• Surgical resection – reserved for confirmed gastrinomas that are localized and resectable; also considered for refractory ulcer disease unresponsive to medical therapy.
• Radiofrequency ablation or embolization – for unresectable gastrinomas when symptom control is needed.

Lifestyle and Dietary Modifications

• Avoid foods that stimulate acid secretion: spicy foods, caffeine, alcohol, carbonated beverages.
• Eat smaller, more frequent meals to reduce gastric load.
• Maintain adequate hydration to offset diarrhea‑related losses.
• Quit smoking – nicotine promotes gastric acid production and impairs ulcer healing.
• Limit NSAID and aspirin use unless under physician guidance.

Living with Zollinger‑Ellison‑Like Gastrin Hypersecretion

Managing a chronic condition requires daily habits that complement medical therapy.

Practical Tips

• Medication adherence – take PPIs 30 minutes before breakfast; set phone reminders.
• Track symptoms – use a simple diary (pain intensity, stool frequency, weight changes) to discuss trends with your doctor.
• Regular monitoring – repeat fasting gastrin and serum acid tests every 6–12 months, or sooner if symptoms change.
• Bone health surveillance – baseline DEXA scan and repeat every 2–3 years if on high‑dose PPIs long‑term.
• Vaccinations – patients on chronic PPIs may have reduced absorption of certain vaccines; stay up‑to‑date with influenza, pneumococcal, and COVID‑19 vaccines.
• Stress management – chronic pain can amplify stress hormones, which in turn increase acid secretion. Mind‑body techniques (yoga, meditation) are beneficial.

Support Resources

Connecting with patient support groups (e.g., American Gastroenterological Association forums) can provide emotional support and practical advice.

Prevention

While it is impossible to prevent all cases, especially those related to an underlying tumor, several measures can reduce the risk of developing non‑neoplastic gastrin hypersecretion.

• Use the lowest effective dose of PPIs and limit duration to the shortest period needed; consider stepping down to H2‑blockers or intermittent dosing once ulcer disease is controlled.
• Screen for and eradicate Helicobacter pylori infection early—testing is recommended for all adults with dyspepsia.
• Maintain kidney health through blood pressure control, glycemic management, and avoidance of nephrotoxic drugs.
• Adopt a balanced diet rich in fruits, vegetables, and whole grains to support mucosal health.
• Regular check‑ups for individuals with MEN 1 or a family history of neuroendocrine tumors.

Complications

If left untreated or inadequately controlled, persistent acid hypersecretion can lead to serious health problems.

• Chronic peptic ulcer disease – can result in perforation, which is a surgical emergency.
• Upper GI bleeding – may cause anemia, hemodynamic instability, and require transfusion.
• Stricturing of the duodenum or jejunum – leads to obstruction and malnutrition.
• Pancreatic enzyme inactivation – chronic malabsorption, weight loss, and fat‑soluble vitamin deficiencies (A, D, E, K).
• Colon cancer risk – some studies suggest that chronic acid exposure may alter mucosal turnover, though data are limited.
• Bone demineralization – long‑term hyperacidic environment impairs calcium absorption, increasing fracture risk.
• Metastatic gastrinoma – if an occult gastrinoma is later discovered, delayed diagnosis can allow tumor spread.

When to Seek Emergency Care

---

For personalized guidance, always discuss your symptoms, test results, and treatment plan with a gastroenterologist or your primary‑care physician. The information above reflects current knowledge from reputable sources such as the Mayo Clinic, CDC, NIH, WHO, and the Cleveland Clinic, but does not replace professional medical advice.

```